Trial reportSurgery today2010
Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors.
Trial report in Surgery today, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Neoadjuvant Imatinib in Recurrent/Metastatic Gastrointestinal Stromal Tumors: A Systematic Review and Meta-analysis of Proportions.Journal of gastrointestinal cancer · 2025Pooled it
- Liver resection for metastatic GIST tumor improves survival in the era of tyrosine kinase inhibitors: a systematic review and meta-analysis.Langenbeck's archives of surgery · 2023Pooled it
- The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review.Langenbeck's archives of surgery · 2014Pooled it
- Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study.Acta oncologica (Stockholm, Sweden) · 2024Trial
- Long-Term Survival Following Multimodal Therapy with Sunitinib and Surgery for Recurrent Duodenal Gastrointestinal Stromal Tumor.Surgical case reports · 2025Article
- Review
- Advances of endoscopic and surgical management in gastrointestinal stromal tumors.Frontiers in surgery · 2023Review
- Hepatic metastases in gastrointestinal stromal tumors: oncologic outcomes with curative-intent hepatectomy, resection of treatment-resistant disease, and tyrosine kinase inhibitor therapy alone.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2022Article
- Review
- Article
- Current treatment strategies and future perspectives for gastrointestinal stromal tumors.World journal of gastrointestinal pathophysiology · 2022Review
- [Surgical and interdisciplinary treatment of gastrointestinal stromal tumors].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2022Review
- Might Patients with Metastatic Gastrointestinal Stromal Tumors Benefit from Operative Management? A Population-Based Retrospective Study.BioMed research international · 2022Article
- Recurrence of gastric gastrointestinal stromal tumor 12 years after repeat hepatectomies for liver metastases: report of a case.Clinical journal of gastroenterology · 2021Article
- Surgical Management of Metastatic Gastrointestinal Stromal Tumors.Current treatment options in oncology · 2021Review
- Solitary peritoneal metastasis of gastrointestinal stromal tumor: A case report.World journal of gastroenterology · 2020Article
- Resection Combined with TKI Therapy for Resectable Liver Metastases of Gastrointestinal Stromal Tumours: Results from Three National Centres in China.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020Article
- Outcomes After Surgical Resection Differ by Primary Tumor Location for Metastatic Gastrointestinal Stromal Tumors (GISTs): a Propensity Score Matching Population Study.Journal of gastrointestinal cancer · 2019Article
- Preoperative therapy with sunitinib malate in a patient with a gastrointestinal stromal tumor and liver metastases: A case report.Medicine · 2019Article
- Role for targeted resection in the multidisciplinary treatment of metastatic gastrointestinal stromal tumor.Translational gastroenterology and hepatology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effectiveness of resecting liver metastases of gastrointestinal stromal tumors (GISTs), when performed in conjunction with imatinib treatment.
methodsForty-one patients with pathologically diagnosed GIST and liver metastases were randomly assigned to an operation group (neoadjuvant therapy + resection + adjuvant therapy with imatinib) or a nonoperation group (imatinib alone). Patients were monitored for up to 36 months, and survival was analyzed.
resultsWe monitored 39 patients throughout the 36-month follow-up period, recording 1- and 3-year survival rates of 100% and 89.5% in the operation group and 85% and 60% in the nonoperation group, respectively. There was a significant difference in overall survival between the operation and nonoperation groups (P = 0.03). Furthermore, resection improved the survival of patients who responded poorly to 6 months of preoperative imatinib treatment, compared with that of their counterparts in the nonoperation group (P = 0.04).
conclusionThese findings suggest that surgical intervention in combination with imatinib treatment is more effective than imatinib alone against GIST liver metastases, with minimal complications and side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.